EGFR and lung cancer: The upregulation of BCAT1 facilitates glutamate–cysteine ligase catalytic subunit‐mediated GSH synthesis and leads to tyrosine kinase inhibitor (TKI) resistance in human epidermal growth factor receptor (EGFR) mutant lung cancer cells [25].